i3 Health recently hosted Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, an accredited CME/NCPD webinar now available on the i3 Health website. In this video interview, Dr. Tolaney shares a preview of the important topics discussed in the activity, including approaches to treatment selection, the emerging role of novel therapies, timely management of adverse events, and much more. Oncology Data Advisor:...

i3 Health is honored to be awarded 4 years of Joint Accreditation for Interprofessional Continuing Education™ (IPCE) as a provider of continuing education for the interprofessional team by the governing bodies of the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center's Accreditation Program (ANCC). i3 Health is pleased to be among the organizations in the United States and throughou...

Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about wh...

An educational enduring online activity provided by i3 Health has demonstrated knowledge gains pertaining to up-to-date treatment and personalized health care plans for metastatic colorectal cancer (CRC). Recently the American Cancer Society estimated that CRC would see 151,030 new cases, with 52,580 of these diagnoses being fatal, this year alone, making CRC the third most commonly diagnosed cancer in the United States. If found early, CRC can be and is often cured, with a 5-year survival rate ...

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for the management and treatment of patients with myelofibrosis. Myelofibrosis, considered a form of chronic leukemia, is a rare type of myeloproliferative neoplasm. An estimated one-third of individuals who have myelofibrosis will not show any symptoms in the early stages of the disorder, which can last many years. However, as the disease develops, they will begin to exhibit symptoms s...

An educational live and enduring activity provided by i3 Health has demonstrated increased expertise and learning outcomes for treatment of patients with prostate cancer. Prostate cancer is the most common cancer in American men, seeing an average of 1 out of 8 men being diagnosed with it within their lifetime. The typical treatment for progressive prostate disease is androgen deprivation therapy (ADT); however, it is common for prostate cancer to become castration-resistant or resistant to ADT....

i3 Health's study focusing on the effectiveness of a nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of the individualized treatment of patients with non-Hodgkin lymphoma (NHL) has been published as a 47th Annual Oncology Nursing Society (ONS) Congress online abstract. The abstract, authored by Elizabeth Heller, PhD; Keira Smith, BA; Kristin Wright, PharmD; and Sarah Williams, MAT, of i3 Health, and Maria Badillo, MSN, RN, OCN®, CCRP, Researc...

i3 Health would like to cordially invite you to our upcoming event, Diagnosis and Evidence-Based Management of T-Cell Lymphoma, a live CME/NCPD-approved webinar. Due to high demand, we are pleased to offer two dates and times for this expert-led discussion: Monday, June 13, 2022, at 3:00 PM EDT, and Friday, June 17, 2022, at 12:00 PM EDT. T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States. The clinical and patho...

Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinically relevant therapies. This educational gap in the treatment and management of follicular lymphoma...

Lung cancer is diagnosed in approximately 235,760 individuals in the United States each year, and 131,880 people die of the disease annually. Non-small cell lung cancer (NSCLC), which accounts for 84% of these cases, has a dismal 5-year survival rate of 18%, and most patients will develop progressive disease within 5 months of their final cycle of first-line classical doublet chemotherapy. The use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers ha...

A shortfall in knowledge in the use of biomarkers and patient-related factors for the personalization of treatment for patients with advanced urothelial carcinoma was identified in the baseline data collected from i3 Health's continuing medical education (CME)–approved visiting faculty meeting series titled New Thinking, New Strategies in Advanced Urothelial Carcinoma, led by Arjun V. Balar, MD, Associate Professor of Medicine and Director of the Genitourinary Medical Oncology Program at NYU Lan...

In order to identify the continuing medical education needs and preferences of hematology/oncology fellows, i3 Health administered a survey to participants at several live CME-certified visiting faculty meetings. i3 Health intends to use the results gathered from the survey in the planning and implementation of CME-certified activities. Of the 54 participants who completed surveys, 80% felt that they had adequate time for self-education activities during their fellowship program, compared with 2...

At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats in which they wished to receive continuing medical education (CME). Thirty-six individuals completed the survey, of whom 35 (97.2%) were physicians and other prescribers of medication. Results showed that despite the ever-increasing ubiquity of technology in our society, uro...

As the number of treatments for recurrent ovarian cancer expands, confusion may develop over which therapeutic strategy is best to use. Numerous patient factors need to be taken into account when deciding on a treatment plan, such as patient health status, predictive/prognostic markers, disease-free interval, number of lines and agents used previously, toxicities remaining from previous lines of therapy, and the extent of disease relapse. The new research constantly being conducted creates anoth...

In order to accurately recognize the continuing medical education (CME) needs and preferences of urology/oncology health care providers, i3 Health administered a survey to participants at the 66th Society of Government Service Urologists Kimbrough Urological Seminar. The results obtained from the survey will be used by i3 Health in the planning and implementation of CME-approved activities. Of the 22 participants who completed the survey, 72.7% were urologists, 18.2% were residents, 4.5% were fe...

​In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting concerning the initiative she led at the Association of Community Cancer Centers (ACCC): collaborative learning workshops focused on best practices for immunotherapy in the community setting. What ...